iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data. In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. iRhythm Technologies, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

iRhythm Technologies Inc.

Irhythm Technologies ($IRTC) announced an update on their ongoing clinical study. The Pediatric Adhesion and New Dermal Approach Study, or PANDA, t...

PANDA Trial Completion Puts iRhythm’s Pediatric Growth Story in Focus

Irhythm Technologies (IRTC) has disclosed a new risk, in the Corporate Activity and Growth category. The holding company’s ability to service its o...

Structural Subordination Risk Looms Over iRhythm Holding Company’s Ability to Service 2029 Notes

Irhythm Technologies (($IRTC)) has held its Q1 earnings call. Read on for the main highlights of the call. iRhythm Technologies’ latest earnings ca...

iRhythm Technologies Signals Profitable Growth Amid Overhangs

Goldman Sachs analyst David Roman maintained a Hold rating on Irhythm Technologies yesterday and set a price target of $147.00. The company’s share...

Goldman Sachs Sticks to Their Hold Rating for Irhythm Technologies (IRTC)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Eli Lilly & Co (LLY), Irhythm Technologies (IRTC) an...

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Irhythm Technologies (IRTC) and TELA Bio (TELA)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Irhythm Technologies (IRTC), Pacira Pharmaceuticals ...

Analysts Are Bullish on Top Healthcare Stocks: Irhythm Technologies (IRTC), Pacira Pharmaceuticals (PCRX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Irhythm Technologies (IRTC) and Apogee Therapeutics ...

Current Quarter	$-0.01	Next Quarter	$0.03
Current Year	$0.13	Next Year	$1.31
QoQ Growth	+400.0%	YoY Growth	+907.7%
3Y EPS CAGR	+29.0%	Target Price	$180.93
Consensus	Buy	Upside	+57.5%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	IRTC	$114.85	-1.47%	298.43K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	IRTC	$114.85	-1.5%	298.43K
3
4
5
6

IRTC

IRTC

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get iRhythm Technologies Inc. Data in Excel

Get iRhythm Technologies Inc. Data in Excel